Mehta SH - Search Results

1

Persistence of HIV transmission clusters among people who inject drugs.

Rose R, Cross S, Lamers SL, Astemborski J, Kirk GD, Mehta SH, Sievers M, Martens C, Bruno D, Redd AD, Laeyendecker O. Rose R, et al. Among authors: mehta sh. AIDS. 2020 Nov 15;34(14):2037-2044. doi: 10.1097/QAD.0000000000002662. AIDS. 2020. PMID: 32773483 Free PMC article.

2

Protection against persistence of hepatitis C.

Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas DL. Mehta SH, et al. Lancet. 2002 Apr 27;359(9316):1478-83. doi: 10.1016/S0140-6736(02)08435-0. Lancet. 2002. PMID: 11988247

3

Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus.

Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Sulkowski MS, et al. Among authors: mehta sh. AIDS. 2005 Mar 24;19(6):585-92. doi: 10.1097/01.aids.0000163935.99401.25. AIDS. 2005. PMID: 15802977

4

The effect of HIV infection on overdose mortality.

Wang C, Vlahov D, Galai N, Cole SR, Bareta J, Pollini R, Mehta SH, Nelson KE, Galea S. Wang C, et al. Among authors: mehta sh. AIDS. 2005 Jun 10;19(9):935-42. doi: 10.1097/01.aids.0000171407.30866.22. AIDS. 2005. PMID: 15905674

5

A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users.

Mehta SH, Thomas DL, Sulkowski MS, Safaein M, Vlahov D, Strathdee SA. Mehta SH, et al. AIDS. 2005 Oct;19 Suppl 3:S179-89. doi: 10.1097/01.aids.0000192088.72055.90. AIDS. 2005. PMID: 16251816 Review.

6

Serum albumin as a prognostic indicator for HIV disease progression.

Mehta SH, Astemborski J, Sterling TR, Thomas DL, Vlahov D. Mehta SH, et al. AIDS Res Hum Retroviruses. 2006 Jan;22(1):14-21. doi: 10.1089/aid.2006.22.14. AIDS Res Hum Retroviruses. 2006. PMID: 16438640

7

HIV incidence among injection drug users in Baltimore, Maryland (1988-2004).

Mehta SH, Galai N, Astemborski J, Celentano DD, Strathdee SA, Vlahov D, Nelson KE. Mehta SH, et al. J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):368-72. doi: 10.1097/01.qai.0000243050.27580.1a. J Acquir Immune Defic Syndr. 2006. PMID: 16980912

8

Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.

Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, Thomas DL, Sulkowski MS. Mehta SH, et al. AIDS. 2006 Nov 28;20(18):2361-9. doi: 10.1097/QAD.0b013e32801086da. AIDS. 2006. PMID: 17117023

9

CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection.

Netski DM, Mosbruger T, Astemborski J, Mehta SH, Thomas DL, Cox AL. Netski DM, et al. Among authors: mehta sh. J Infect Dis. 2007 Mar 15;195(6):857-63. doi: 10.1086/511826. Epub 2007 Feb 7. J Infect Dis. 2007. PMID: 17299716

10

Progression of fibrosis during chronic hepatitis C is associated with rapid virus evolution.

Wang XH, Netski DM, Astemborski J, Mehta SH, Torbenson MS, Thomas DL, Ray SC. Wang XH, et al. Among authors: mehta sh. J Virol. 2007 Jun;81(12):6513-22. doi: 10.1128/JVI.02276-06. Epub 2007 Feb 28. J Virol. 2007. PMID: 17329332 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

477 results

Search Page